# OnCo record elevar-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/elevar-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "elevar-therapeutics" ;
  schema:name "Elevar Therapeutics (HLB)"@en ;
  schema:description "Elevar Therapeutics developed rivoceranib, whose combination with camrelizumab has beaten sorafenib in liver cancer but has been refused by the FDA three times on manufacturing grounds."@en ;
  schema:url <https://onco.cc/companies/elevar-therapeutics/>, <https://elevartherapeutics.com> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://www.targetedonc.com/view/fda-passes-again-on-approving-rivoceranib-plus-camrelizumab-in-hcc> ;
  schema:addressCountry "US" ;
  onco:related <https://onco.cc/collections/src-targeted-oncology/> ;
  onco:cancers <https://onco.cc/cancers/hcc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:drugs <https://onco.cc/drugs/camrelizumab-rivoceranib/>, <https://onco.cc/drugs/lirafugratinib/> ;
  onco:trials <https://onco.cc/trials/nct07359820/> .